Pharmaceuticals

◼ Archived Health

GLP-1 drugs dubbed ‘fountain of youth’ as doctors share surprising benefits beyond weight loss

GLP-1 medications face growing attention for unexpected health benefits and wider usage trends beyond weight management.

7 sources 7 articles v 5 3d ago

◼ Archived Business

AstraZeneca Breast-Cancer Drug Misses Goal in Late-Stage Trial

AstraZeneca's breast cancer pill Etcamah missed its primary goal in a late-stage trial, adding to oral SERD failures.

9 sources 10 articles v 8 3d ago

◼ Archived Health 🔮 fades ✓

Inappropriate Prescribing Cascades Put Older Adults at Risk

Recent coverage examines inappropriate prescribing cascades where older adults receive new medications to treat side effects.

5 sources 5 articles v 3 4d ago

◼ Archived Business 🔮 fades ✓

A Promising Heart Drug Failed. What Went So Wrong?

The failure of heart drug trials from pharmaceutical giants Novartis and Novo Nordisk creates a significant setback for a promising field of medicine.

2 sources 2 articles v 4 6d ago

◼ Archived Business 🔮 fades ✓

Takeda’s long-serving R&D chief Andy Plump to retire in wake of pipeline successes

Takeda Pharmaceutical's R&D chief Andy Plump is set to retire in June 2027 following a period of significant pipeline reorganization and regulatory success.

7 sources 8 articles v 5 6d ago

◼ Archived Business 🔮 fades ✗

Novartis shareholder calls for board overhaul following costly deal setbacks: Reuters

A major Novartis shareholder is demanding a board overhaul following a series of costly drug trial setbacks and strategic failures.

6 sources 7 articles v 4 5d ago

◼ Archived Business 🔮 fades ✓

Insilico's co-CEO hopes 'we might have a chance to stop biological aging'

Recent coverage explores potential links between a lung disease drug and the slowing of biological aging.

2 sources 2 articles v 1 7d ago

◼ Archived Business 🔮 fades ✗

A New Drug Lifts the Fog of Sleepiness for Those With Narcolepsy

Takeda has released Phase 3 study data for oveporexton, a new drug designed to treat the excessive daytime sleepiness associated with narcolepsy.

6 sources 6 articles v 4 7d ago

◼ Archived Business 🔮 fades ✓

How Novartis' Double-Stacked Failures Shook Biotech

Novartis is facing significant scrutiny within the biotech sector following a series of dual failures that have impacted investor confidence.

1 sources 1 articles v 0 8d ago

◼ Archived Business 🔮 fades ✓

A breakthrough pancreatic cancer drug won approval. They still struggle to access it

A breakthrough pancreatic cancer drug wins FDA approval and hits the clinic, raising questions over patient access.

6 sources 6 articles v 4 7d ago

◼ Archived Business 🔮 fades ✓

AZ's R&D chief Barr touts internal 'science success story' after IL-33 antibody's stellar showing in COPD

AstraZeneca reports positive Phase III trial results for tozorakimab, a drug targeting COPD exacerbations.

2 sources 2 articles v 1 7d ago

◼ Archived Business 🔮 fades ✓

An AI-developed drug appeared to make patients biologically younger in a clinical trial

A clinical trial has indicated that a drug developed through artificial intelligence may have the capacity to make patients biologically younger.

1 sources 1 articles v 0 8d ago

◼ Archived Health 🔮 holds ✗

Alzheimer’s treatment is advancing rapidly

Rapid advancements in medical research and a surge in clinical trials have positioned an Alzheimer's cure as a tangible possibility for the first time.

8 sources 8 articles v 6 8d ago

◼ Archived Business 🔮 fades ✓

New drug shows promise in reducing COPD symptoms in former and current smokers, clinical trials show

AstraZeneca and Sanofi detail new respiratory clinical data at the #ERS26 conference.

1 sources 1 articles v 0 8d ago

◼ Archived Business 🔮 fades ✗

Novartis Stock Tanks Following Third Major Pipeline Setback

Novartis stock experiences a sharp decline following a Phase 3 failure for a dystrophy drug linked to its $12 billion Avidity acquisition.

1 sources 1 articles v 0 8d ago

◼ Archived Health 🔮 fades ✓

Drug developed for lung disease may slow biological aging in surprising ‘bonus’

A drug originally designed to treat lung disease may provide a surprising secondary benefit by slowing the process of biological aging.

1 sources 1 articles v 0 7d ago

◼ Archived Business 🔮 fades ✓

Novartis stock slides as centerpiece of $12B Avidity buyout flunks ‘crucial’ phase 3 test

Novartis shares experienced their worst single-day drop in over two decades following the failure of a crucial phase 3 trial for an Avidity buyout drug.

4 sources 6 articles v 3 8d ago

◼ Archived Health 🔮 fades ✓

Study Suggests AI-Generated Drug Could Slow Aging

A new study suggests that a drug developed through artificial intelligence may have the potential to slow the biological process of aging.

1 sources 1 articles v 0 9d ago

◼ Archived Business 🔮 fades ✗

Novo Nordisk Says Wegovy Shot Helped Children Lose Weight in Trial

Novo Nordisk's Wegovy shows weight-loss results in young children during trial data releases.

7 sources 7 articles v 5 9d ago

◼ Archived Business 🔮 fades ✗

Novo scraps two more heart drug trials, further dimming growth beyond obesity

Novo Nordisk faces a diverging trajectory as it meets pediatric obesity goals but terminates two heart disease drug trials.

2 sources 2 articles v 1 8d ago

◼ Archived Business 🔮 fades ✗

Novartis cholesterol setback tests hopes for emerging heart disease drugs

Novartis shares decline after its cholesterol drug pelacarsen failed a critical late-stage cardiovascular trial, impacting expectations for heart disease treatments.

4 sources 5 articles v 3 9d ago

◼ Archived Business 🔮 fades ✓

Updated: Novo Nordisk cans 2 more trials of IL-6 heart drug for futility

Novo Nordisk has terminated two additional phase 3 trials of its cardiovascular drug ziltivekimab due to futility, impacting its growth strategy.

5 sources 5 articles v 3 10d ago

◼ Archived Health 🔮 fades ✓

(Un)intended consequences of mass-prescribing GLP-1s

Recent reporting examines the widespread prescribing of GLP-1 medications and their broad societal and biological impacts.

1 sources 1 articles v 0 12d ago

◼ Archived Health 🔮 fades ✗

Experimental weight loss jab outperforms Mounjaro in latest study

A new experimental weight loss injection has outperformed Mounjaro in a recent study, signaling a potential shift in obesity treatment.

1 sources 1 articles v 0 12d ago

◼ Archived Business 🔮 fades ✗

Novartis Shares Climb After Pill Hits Goals in Multiple Sclerosis Trials

Novartis shares climb following positive late-stage trial results for its experimental oral multiple sclerosis drug, Rhapsido.

18 sources 19 articles v 20 15d ago

◼ Archived Business 🔮 fades ✗

Eli Lilly inks $2.88B Merida buyout for autoimmune drugs against rogue antibodies

8 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.

8 sources 9 articles v 6 16d ago

◼ Archived Business 🔮 fades ✓

Trump unveils more prescription drug pricing discounts projected to save Americans $600B: 'Major step forward'

3 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.

3 sources 3 articles v 7 16d ago

◼ Archived Business 🔮 holds ✗

Trump reportedly plans to announce new drug pricing deals with nearly a dozen drugmakers

9 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.

9 sources 9 articles v 34 16d ago

◼ Archived Business 🔮 fades ✗

A $480,000-a-Year Pill Reflects a New Normal for Cancer Drugs

13 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.

13 sources 14 articles v 13 14d ago

◼ Archived Business 🔮 fades ✓

Bristol Myers ends deal with Cellares, cell therapy manufacturer to reorg

6 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.

6 sources 6 articles v 4 22d ago

◼ Archived Business 🔮 fades ✓

Roche pens $2.5B pact for Hanmi’s clinical-stage obesity drug targeting less-explored mechanism

7 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.

7 sources 7 articles v 5 23d ago

◼ Archived Business 🔮 fades ✗

Eli Lilly Launches Foundayo Weight-Loss Pill in U.K.

Eli Lilly has introduced Foundayo, a new daily oral weight-loss medication, to the United Kingdom market, driving a significant rise in company stock.

9 sources 9 articles v 7 23d ago

◼ Archived Health 🔮 fades ✗

Your Kidney Disease Risk May Be Increased by This Common Food

3 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.

3 sources 4 articles v 2 23d ago

◼ Archived Business 🔮 fades ✓

Amylyx Stock Surges 55% After GLP-1 Blocker Hits All Trial Goals

4 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.

4 sources 6 articles v 3 29d ago

◼ Archived Health 🔮 fades ✗

A pill that mimics exercise? Early results on drug designed to maintain both weight loss and muscle mass

7 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.

7 sources 7 articles v 5 28d ago

◼ Archived Business 🔮 fades ✓

EyePoint Stock Craters 69% After Drug Trial Failure. It May Be an Overreaction.

2 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.

2 sources 2 articles v 1 29d ago

◼ Archived Health 🔮 fades ✗

Coroner links teenage student’s death to weight-loss drug Mounjaro

3 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.

3 sources 3 articles v 1 36d ago

◼ Archived Health 🔮 fades ✓

UK approves its second weight-loss pill while EU access lags

2 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.

2 sources 2 articles v 1 37d ago

◼ Archived Business 🔮 fades ✓

AbCellera women’s health data top ‘most aggressive upside scenario,’ putting Astellas and Bayer on notice

2 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.

2 sources 3 articles v 1 37d ago

◼ Archived Business 🔮 fades ✗

Why Sionna Therapeutics Stock Is Crashing 91% to a Record Low

3 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.

3 sources 3 articles v 1 37d ago

◼ Archived Business 🔮 fades ✗

Bristol Myers to build $2.3 billion manufacturing site in Houston

4 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.

4 sources 4 articles v 2 36d ago

◼ Archived Business 🔮 fades ✗

Pharma giant bets $2.3B on massive new Houston campus

Pharmaceutical leader Bristol Myers Squibb is investing $2.3 billion to establish a massive new manufacturing campus in Houston, Texas.

10 sources 11 articles v 9 37d ago

◼ Archived Business 🔮 holds ✗

Amgen drops ph. 1 obesity drug, upping pressure on MariTide

10 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.

10 sources 10 articles v 8 43d ago

◼ Archived Business 🔮 fades ✓

Novo outlook hike falls flat as Wegovy pill sales fail to impress

4 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.

4 sources 4 articles v 2 43d ago

◼ Archived Business 🔮 fades ✓

‘Unlikely’ AstraZeneca-BMS mega-merger would be largest pharma deal ever

Analysts express perplexity as reports indicate active merger talks between Bristol-Myers Squibb and AstraZeneca.

2 sources 2 articles v 1 43d ago

◼ Archived Business 🔮 fades ✓

Why Pfizer Just Hiked Its Guidance By $500 Million

3 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.

3 sources 3 articles v 7 44d ago

◼ Archived Business 🔮 fades ✗

Pfizer Covid Pill Revenue Plunges 95%. Why Earnings Are Lifting the Stock Anyway.

Pfizer's stock is rising after beating earnings estimates, despite a 95% plunge in revenue from its Covid pill.

9 sources 9 articles v 13 43d ago

◼ Archived Business 🔮 holds ✓

Eli Lilly to allow more patients to apply for special access to unapproved obesity drug

10 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.

10 sources 11 articles v 9 43d ago

◼ Archived Business 🔮 fades ✗

Merck & Co., Inc., Rahway, N.J., USA Announces Second-Quarter 2026 Financial Results; Highlights Key Regulatory and Clinical Milestones Across Broad, Diverse Pipeline

Merck & Co. reports mixed Q2 2026 results, lifting sales forecasts on drug strength while cutting profit outlook due to acquisition costs.

11 sources 16 articles v 20 41d ago

◼ Archived Business 🔮 fades ✓

What would it take to get peptides on the shelf?

NPR examines the regulatory and commercial hurdles involved in bringing peptide-based products to retail shelves.

2 sources 2 articles v 1 44d ago

◼ Archived Business 🔮 fades ✗

AstraZeneca investors baulk at $400 billion Bristol Myers talks

AstraZeneca investors are resisting proposed acquisition talks with Bristol Myers valued at $400 billion.

9 sources 10 articles v 8 44d ago

◼ Archived Business 🔮 fades ✗

AstraZeneca Shares Fall on Deal Talks With Bristol-Myers

AstraZeneca shares have declined following reports of potential $400 billion merger talks with Bristol Myers Squibb.

4 sources 5 articles v 3 44d ago

◼ Archived Science 🔮 fades ✓

Deadly blooms offer a genetic blueprint for making hard-to-synthesize medicinal compounds

Scientists have discovered that two deadly flowers may provide the genetic blueprint for creating hard-to-synthesize medicinal compounds.

6 sources 7 articles v 4 45d ago

◼ Archived Business 🔮 fades ✓

Novo Nordisk rocked by late-stage cardiovascular drug failure

Pharmaceutical giant Novo Nordisk faces a significant setback following the failure of a late-stage cardiovascular drug trial.

1 sources 1 articles v 0 47d ago

◼ Archived Health 🔮 fades ✓

New, more efficient pill to lower cholesterol

FDA approves first oral PCSK9 inhibitor for adults with high cholesterol, changing treatment options.

1 sources 1 articles v 0 48d ago

◼ Archived Business 🔮 fades ✗

GSK unveils 3-year cost-saving plan to fund late-stage R&D, move research HQ to AZ's backyard

GSK is launching a $2.5 billion cost-saving initiative to accelerate its late-stage drug pipeline and relocate its research headquarters.

9 sources 9 articles v 7 50d ago

◼ Archived Business 🔮 holds ✓

Johnson & Johnson offers to pay $5.5bn to settle baby powder lawsuits

Johnson & Johnson has proposed a $5.5 billion settlement to resolve a decade-long legal battle over cancer claims linked to its baby powder.

16 sources 19 articles v 19 49d ago

◼ Archived Business 🔮 fades ✓

Logistics giants are racing to keep up with healthcare boom as GLP-1s highlight need for cold storage

Logistics giants are aggressively expanding cold storage infrastructure to accommodate a surge in GLP-1 drug demand and a broader healthcare boom.

6 sources 6 articles v 4 53d ago

◼ Archived Business 🔮 fades

US FDA approves over-the-counter Tylenol combination pill for pain relief

The US FDA has approved the first over-the-counter combination of acetaminophen and naproxen sodium for extended pain relief.

14 sources 15 articles v 14 53d ago

◼ Archived Business 🔮 fades

With Hopes High for New H.I.V. Prevention Pill, Merck Takes Steps to Ensure Access

Merck is establishing global access and licensing frameworks for the world's first monthly oral HIV prevention pill ahead of its official approval.

5 sources 5 articles v 14 55d ago